GIT (Drugs For Motility Disorders and Irritable Syndrome) Flashcards

(144 cards)

1
Q

Drugs that can selectively stimulate gut motor function
(prokinetic)

A

DRUGS FOR MOTILITY DISORDER

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

drugs that increases ____________ pressure may be
useful for GERD

A

lower esophageal sphincter pressure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Increase lower esophageal sphincter pressure may be
useful for

A

GERD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Improves gastric emptying may be helpful for ________ and ________

A

gastroparesis; post surgical gastric emptying delay

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

CHOLINOMIMETICS will reduce ________

A

LES sphincter tone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Stimulate muscarinic M3 receptor on muscle cell and at
myenteric plexus synapse

A

BETANECHOL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

BETANECHOL is used in the past for the treatment of _______ and
____________

A

GERD and gastroparesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Used in the past for the treatment of GERD and
gastroparesis

A

BETANECHOL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

T/F: Betanechol is no longer used due to toxic effect

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Motility Disorder Drugs that is also an Acetylcholinesterase inhibitor

A

NEOSTIGMINE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what does NEOSTIGMINE inhibits

A

Acetylcholinesterase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Can enhance gastric and small intestine and colonic
emptying

A

NEOSTIGMINE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Administration of ______ of Neostigmine may lead to evacuation of the feces

A

2mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Side Effects of Neostigmine

A

○ Excessive salivation
○ Bradycardia
○ Nausea
○ Vomitting
○ Diarrhea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Used in hospitals for acute bowel distention

A

NEOSTIGMINE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Activation of dopamine receptor inhibits ________________ therefore its blockade is
believed to be the primary prokinetic mechanism

A

cholinergic
smooth muscle stimulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

primary prokinetic mechanism

A

blockade of cholinergic smooth muscle stimulation caused by the activation of dopamine receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Movement in the GI is faster if _________ is blocked

A

dopamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

D2 blockade causes (increase/decrease) bowel transit

A

increased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

METOCLOPROMIDE (can/cannot) cross the blood brain barrier (BBB)

A

can

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Blocks D2 receptor in the chemoreceptor trigger zone
(CTZ) of the medulla, resulting in potent antinausea and
antiemetic action

A

METOCLOPROMIDE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

METOCLOPROMIDE blocks D2 receptor in the chemoreceptor trigger zone
(CTZ) of the medulla, resulting in potent _______ and ________ action

A

potent antinausea and
antiemetic action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Metoclopromide blocks D2 receptor in the _______________ of the medulla, resulting in potent antinausea and
antiemetic action

A

chemoreceptor trigger zone
(CTZ)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

May also cause parkinsonian symptoms (dystonia,
akathisia, parkinsonian)

A

METOCLOPROMIDE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
D2 Antagonist that does not cross the blood-brain barrier; less likely to cause CNS effects
DOMPERIDONE
26
T/F: Domperidone does not have anti-emetic property
T
27
only improves motility → transit of the bowel
DOMPERIDONE
28
MOTILIN RECEPTOR AGONISTs
Erythromycin
29
Erythromycin is classified under ________ antibiotics
macrolides
30
Stimulates the motilin receptors on gastrointestinal smooth muscle and promote the onset of a migrating motor complex
Motilin Receptor Agonist (Erythromycin)
31
Motilin Receptor Agonist stimulates the motilin receptors on gastrointestinal smooth muscle and promote the onset of a _______________
migrating motor complex
32
form and dose of erythromycin that is beneficial in some patients with gastroparesis
IV erythromycin (3 mg/kg)
33
Used in patients with acute upper gastrointestinal hemorrhage to promote gastric emptying of blood before endoscopy
Motilin Receptor Agonist (Erythromycin)
34
ADRs of Motilin Receptor Agonist (Erythromycin)
Diarrhea Gastroparesis
35
T/F: Tolerance can be rapidly developed in Erythromycin
T
36
LAXATIVES
BULK FORMING LAXATIVE STOOL SURFACTANT AGENTS (SOFTENER) OSMOTIC LAXATIVE BALANCED POLYETHYLENE GLYCOL STIMULANT LAXATIVE DIPHENYLMETHANE DERIVATIVE
37
BULK FORMING LAXATIVEs
Psyllium, Methylcellulose, Polycarbophil
38
Indigestible, hydrophilic colloids that absorb water, forming bulky, emollient get that distends the colon and prompt peristalsis
BULK FORMING LAXATIVE (Psyllium, Methylcellulose, Polycarbophil)
39
STOOL SURFACTANT AGENTS (SOFTENER)
Docusate, glycerin and mineral oil
40
Soften stool material, permitting water and lipids to penetrate
STOOL SURFACTANT AGENTS (Docusate, glycerin and mineral oil)
41
STOOL SURFACTANT AGENTS May be administered _________ or ________
orally or rectally
42
lubricates fecal material, retarding water absorption from the stool
Mineral oil
43
Used to prevent the impaction of the fecal matters
Mineral oil
44
Long term use impairs absorption particularly insoluble vitamins (Vit. A, D, E, K
STOOL SURFACTANT AGENTS (Docusate, glycerin and mineral oil)
45
Soluble but nonabsorbable compound (sugar) that result in increased stool liquidity due to an obligate increase in fecal flui
OSMOTIC LAXATIVE
46
Nonabsorbable sugar or salt (Osmotic Laxative) is used for the treatment of ________ or the prevention of ________
acute constipation or the prevention of chronic constipation
47
Commonly used osmotic laxative
Magnesium hydroxide (Milk of Magnesia)
48
Magnesium hydroxide should not be used for prolonged period in patients with _______________ due to the risk of hypermagnesemia
renal insufficiency
49
Nonabsorbable sugar that can be used to prevent or treat chronic constipation
Sorbitol and Lactulose
50
Sorbitol and Lactulose are metabolized by ____________ producing severe flatulence and cramps
colonic bacteria
51
These sugar are metabolized by colonic bacteria producing severe flatulence and cramps
Sorbitol and Lactulose
52
High doses of osmotically active agents produces prompt bowel evacuation within
1 to 3 hours
53
May be used for the treatment of acute constipation or to cleanse the bowel prior to medical procedure
OSMOTIC LAXATIVE
54
infrequently used osmotic laxative due to the risk of hyperphosphatemia
Sodium phosphate
55
Osmotic Laxatives
* Absorbable sugars * Nonabsorbable sugars: * Magnesium hydroxide (Milk of Magnesia) * Sorbitol and Lactulose * Sodium phosphate
56
Used for complete colonic cleansing before gastrointestinal endoscopic procedure
BALANCED POLYETHYLENE GLYCOL
57
Inert, nonabsorbable, osmotically active sugar (PEG) with sodium sulfate, sodium chloride, sodium bicarbonate and potassium chloride
BALANCED POLYETHYLENE GLYCOL
58
Designed so that no IV fluid and electrolyte shift will occur
BALANCED POLYETHYLENE GLYCO
59
For opitmal bowel cleansing ____ to ______ liters of BALANCED POLYETHYLENE GLYCOL solution should be ingested rapidly (over 1 to 2 hours) on the evening before the procedure and again in ___ to ___ hours before the procedure.
1 to 2 L; 4 to 6 hours
60
For treatment or prevention of chronic constipation, smaller doses of _____________ may be mixed with water or juice (17 g/8 oz)
PEG powder
61
Induce bowel movements through a number of poorly understood mechanisms
STIMULANT LAXATIVE
62
Direct stimulation of the enteric nervous system and colonic electrolyte and fluid secretion
STIMULANT LAXATIVE
63
Anthraquinone Derivative
STIMULANT LAXATIVE
64
Anthraquinone Derivative (plants)
Aloe, senna, cascara sagrada
65
Poorly absorbed and after hydrolysis in the colon, produce a bowel movement in 6 to 12 hours when given orally and within 2 hours when given rectall
Anthraquinone Derivative
66
Chronic use of Anthraquinone Derivative causes __________
melanosis coli
67
Carcinogenic
Anthraquinone Derivative
68
DIPHENYLMETHANE DERIVATIVEs
Bisacodyl (Dulcolax)
69
Bisacodyl is used for the treatment of ________ and ________
acute and chronic constipation
70
Used in conjunction with PEG solution for colonic cleansing prior to colonoscopy
DIPHENYLMETHANE DERIVATIVE (Bisacodyl)
71
Bisacodyl Induces bowel movement within ______ to _______ hours when given orally and ______ to ______ minutes when taken rectally
6 to 10 hours orally; 30 to 60 rectally
72
CHLORIDE CHANNEL ACTIVATORs
LUBIPROSTONE LINACLOTIDE
73
Prostanoic acid derivative labeled for use in chronic constipation and irritable bowel syndrome (IBS)
LUBIPROSTONE
74
Stimulating the type 2 chloride channel (CIC-2) in the small intestine
LUBIPROSTONE
75
LUBIPROSTONE stimulates the _________ in the small intestine
type 2 chloride channel (CIC-2)
76
Increases the chloride rich fluid secretion into the intestine, which stimulate intestinal motility and shortens intestinal transit time
LUBIPROSTONE
77
LUBIPROSTONE increases the _______ rich fluid secretion into the intestine, which stimulate intestinal motility and (shortens/lengthens) intestinal transit time
chloride; shortens
78
_________ mcg of LUBIPROSTONE orally ______ daily is recommended dose for treatment of chronic constipation
24; twice
79
T/F: There is no loss of efficacy if Lubiprostone is taken as long term therapy
T
80
Minimally absorbed Chloride Channel Activator
LINACLOTIDE
81
14 amino acid peptide that stimulates intestinal chloride secretion through a different mechanism
LINACLOTIDE
82
LINACLOTIDE is approved for the treatment of chronic constipation and _____________
IBS with predominant constipation
83
Binds to and activates guanylyl cyclase-C on the luminal intestinal epithelial surface, resulting in increased intracellular and extracellular cGMP that leads To activation of the cystic fibrosis transmembrane conductance regulator (CFTR) leading to increased chloride rich secretion and acceleration of intestinal transit
LINACLOTIDE
84
LINACLOTIDE binds to and activates guanylyl cyclase-C on the ____________, resulting in ______(increased/decreased) intracellular and extracellular cGMP that leads To activation of the ________________leading to increased chloride rich secretion and acceleration of intestinal transit
luminal intestinal epithelial surface; increased; cystic fibrosis transmembrane conductance regulator (CFTR)
85
OPIOID RECEPTOR ANTAGONIST
METHYLNALTREXONE BROMIDE AND ALVIMOPAN
86
Acute and chronic therapy with opioids may cause ___________ by decreasing intestinal motility, which results in _________ transit time and _________ absorption of fecal water
constipation; prolongs; increased
87
METHYLNALTREXONE BROMIDE AND ALVIMOPAN (Do not readily cross/ Readily cross) the blood-brain barrier
Do not readily cross the blood-brain barrier
88
inhibit peripheral µ-opioid receptor without impacting analgesic effects within the CNS
METHYLNALTREXONE BROMIDE AND ALVIMOPAN
89
METHYLNALTREXONE BROMIDE AND ALVIMOPAN inhibit peripheral µ-opioid receptor _____(with/without) impacting analgesic effects within the CNS
without
90
Treatment of opioid induced constipation; administered SQ (0.15 mg/kg) every 2 days.
Methylnaltrexone
91
Short term used to shorten the period of postoperative ileus in hospitalized.
Alvimopan
92
Opiod antagonist that have cardiotoxic effect
Alvimopan
93
Opiod antagonist that doesnt have pschological/CNS effects
Methylnaltrexone
94
SEROTONIN 5-HT4 RECEPTOR AGONISTs
TEGASEROD PRUCALOPRIDE
95
Stimulation of ____________ on the presynaptic terminal of submucosal intrinsic primary afferent nerves enhances the release of their neurotransmitters, including __________, which stimulates second order enteric neurons to promote the__________
5-HT4 receptor; gene related peptide; peristaltic reflex
96
Serotonin 5-HT4 partial agonist that has high affinity for 5-HT4 receptor but no appreciable binding 5-HT3 or dopamine receptor
TEGASEROD
97
TEGASEROD is approved for the treatment of patients with chronic constipation and ______________
IBS with predominant constipation
98
High affinity 5-HT4 agonist available in Europe
PRUCALOPRIDE
99
PRUCALOPRIDE is used as treatment for chronic constipation in ______
women
100
ANTIDIARRHEAL treats _______
Mild to moderate diarrhea
101
Can Antidiarrheals be used for patients with bloody diarrhea, high fever and systemic toxicity?
No, If given, it can worsen underlying conditions becase it increases the colonic phasic activity inhibiting the stimulation of the GI
102
OPIOID AGONISTs
Loperamide Diphenoxylate Kaolin Pectin Combined: Kaolin-Pectin
103
Increase colonic phasic segmenting activity through inhibition of presynaptic cholinergic nerve in the submucosal and myenteric plexuses and lead to increased colonic transit time and fecal water absorption.
OPIOID AGONIST
104
Opioid agonist that does not cross the blood-brain barrier
Loperamide
105
Opioid agonist that has no analgesic properties or potential addiction
Loperamide
106
Prescription opioid agonist that has no analgesic properties in standard doses
Diphenoxylate
107
Higher doses have CNS effect, and prolonged use can lead to opioid dependence
Diphenoxylate
108
Naturally hydrated magnesium aluminum silicate
Kaolin
109
Indigestible carbohydrate from apple
Pectin
110
Absorbs bacterial toxin and fluids
Pectin
111
T/F: Combined: Kaolin-Pectin may interfere with the absorption of other drugs
T
112
T/F: Combined: Kaolin-Pectin can cause constipation
T
113
Conjugated bile salt normally absorbed in the terminal ileum
BILE SALT BINDING RESIN
114
BILE SALT BINDING RESINs
Cholestryramine, Colestipol and Colesevelam
115
BILE SALT BINDING RESIN is normally absorbed in the
terminal ileum
116
May decrease diarrhea caused by excess fecal bile acid
BILE SALT BINDING RESIN
117
BILE SALT BINDING RESIN ADRs
○ Bloating ○ Flatulence ○ Constipation ○ Fecal impaction
118
OCTREOTIDEs
SOMATOSTATIN
119
T/F: Somatostatin is not a statin
T
120
14 amino acid peptide that released in the gastrointestinal tract and pancreas from paracrine cell, D cells and enteric nerve as well as from hypothalamus
SOMATOSTATIN
121
nhibits the secretion of numerous hormones and transmitter including gastrin, cholestykinin, growth hormones
SOMATOSTATIN
122
SOMATOSTATIN inhibits the secretion of numerous hormones and transmitter including ______, __________, ____________
gastrin, cholestykinin, growth hormones
123
Reduces intestinal fluid secretion and pancreatic secretion
SOMATOSTATIN
124
Slows gastrointestinal motility and inhibits gallbladder contraction
SOMATOSTATIN
125
Reduces portal and splanchnic blood flow
SOMATOSTATIN
126
Inhibits secretion of some anterior pituitary hormone
SOMATOSTATIN
127
Clinical usefulness of somatostatin is limited by its ________( short/long) half-life in the circulation
short
128
Somatostatin can inhibit _________ and reduce __________: Inhibits: -secretion of numerous hormones and transmitter including ___________________ secretion of _________________ Reduces - _____________ secretion and ________ secretion - _________ and _________ blood flow
Inhibits: -secretion of numerous hormones and transmitter including **gastrin**, **cholestykinin**, **growth** hormones -secretion of some **anterior** **pituitary** hormone Reduces - **intestinal** **fluid** secretion and **pancreatic** secretion - **portal** and **splanchnic** blood flow
129
an idiopathic chronic, relapsing disorder characterized by abdominal discomfort (pain, bloating, distention or cramps) in association with alterations in bowel habits (diarrhea, constipation
IBS
130
Pharmacologic therapy for IBS are directed at __________ and __________
relieving abdominal pain and discomfort and improving bowel function
131
ANTISPASMODIC (ANTICHOLINERGIC) Drugs
Dicyclomine and Hyoscyamine
132
Works primarily through anticholinergic activities
ANTISPASMODIC (ANTICHOLINERGIC)
133
Inhibits muscarinic cholinergic receptor in the enteric plexus and on smooth muscle
Dicyclomine and Hyoscyamine
134
Used to relieve abdominal pain
Dicyclomine and Hyoscyamine
135
At lower dose, Dicyclomine and Hyoscyamine exhibits
minimal autonomic effect
136
At a higher dose, Dicyclomine and Hyoscyamine exhibits
significant anticholinergic effect
137
activate **visceral** afferent pain sensation via **extrinsic sensory neurons** from the gut to the spinal cord and central nervous system
5-HT3 receptor
138
Inhibition of afferent gastrointestinal 5-HT3 receptor may _____(increase/reduce) unpleasant visceral afferent sensation, including nausea, bloating and pain
reduce
139
Highly potent and selective antagonist of the 5-HT3 receptor
Alosterin
140
Alosterin is rapidly absorbed from the gastrointestinal tract with a bioavailability of 50 to 60%, and has a plasma half-life of ____________ but a much longer duration of effect
1.5 hours
141
Alosterin undergoes extensive _____________ with renal excretion of most metabolite
hepatic cytochrome P450 metabolism
142
Alosterin binds with ________ affinity and dissociates _________ from 5-HT3 which accounts for its long duration of action
higher; more slowly
143
Alosterin is approved for the treatment of women with __________ in whom diarrhea is the predominant symptoms
severe IBS
144
Drugs that are approved for the treatment of chronic constipation and IBS with predominant constipation
LINACLOTIDE TEGASEROD Alosterin (for women)